Issues - Novembre 2024

Nader-Marta G, Singer C, Hlauschek D, et al.

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

Breast Cancer Res 2024;26(1):140

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Gjesvik J, Moshina N, Lee CI, et al.

Artificial intelligence algorithm for subclinical breast cancer detection

JAMA Netw Open 2024;7(10):e2437402

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Gannon MR, Dodwell D, Miller K, et al.

Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: a national population-based cohort study using routine data

Eur J Cancer 2024;211:114309

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Kimmick G, Pilehvari A, You W, et al.

First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting

Breast Cancer Res Treat 2024;208(2):263-273

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Pilehvari A, Kimmick G, You W, et al.

Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting

Breast Cancer Res 2024;26(1):144

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

Simonpietro Marrocco Issues, Novembre 2024

Leggi abstract

---

Schmid P, Cortes J, Dent R, et al.

Overall survival with pembrolizumab in early-stage triple-negative breast cancer

N Engl J Med 2024 Sep 15. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Bardia A, Hu X, Dent R, et al.

Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer

N Engl J Med 2024 Sep 15. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

De Sanctis R, Tiberio P, Jacobs F, et al.

Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer

Oncologist 2024;29(9):e1113-e1119

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Qureshi Z, Jamil A, Fatima E, et al.

Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: a systematic review and meta-analysis

Am J Clin Oncol 2024 Sep 9. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Dilawari A, Buturla J, Osgood C, et al.

US Food and Drug Administration approval summary: capivasertib with fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN alterations

J Clin Oncol 2024 Aug 19:JCO2400427. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Oliveira M, Rugo HS, Howell SJ, et al.

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Lancet Oncol 2024;25(9):1231-1244

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Zuley ML, Bandos AI, Duffy SW, et al.

Breast cancer screening interval: effect on rate of late-stage disease at diagnosis and overall survival

J Clin Oncol 2024 Aug 21:JCO2400285. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

• ← Previous
• Next →